All In Biotech

Drug Trial Radar · NCT05928169

Determinants of Chronic Inflammatory Skin Disease Trajectories

Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

May 1, 2023

Primary completion

Apr 30, 2032

Study completion Dec 31, 2032

Sponsor

Lead sponsor
University Hospital Schleswig-HolsteinAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 3, 2023

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 0 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Although it is well known that the clinical expression and course of chronic inflammatory skin diseases are highly variable, there are insufficient epidemiological data on this, and the factors that determine the manifestation, clinical features and course are also largely unknown. There are currently no reliable markers that could predict or delineate patient subgroups to support patient management. The aim of this project is to identify clinical and molecular factors that correlate with disease, disease subtypes and progression through in-depth long-term clinical characterization of patients with chronic inflammatory skin diseases and examination of individual biomaterials.

Conditions

  • Atopic Dermatitis
  • Psoriasis
  • Lichen Planus
  • Alopecia Areata
  • Hidradenitis Suppurativa
  • Prurigo Nodularis
  • Cutaneous Lupus
  • Rosacea

Interventions

  • Topical and systemic drugsDrug

    Observational study, treatment decisions are made independently as part of routine clinical care. Recruitment and follow-up will be independent on the type of treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Physician-assessed global disease activityTime frame: Baseline, week 2, week 4, every 3 months up to 2 years
  2. Patient-reported global disease activityTime frame: Baseline, week 2, week 4, every 3 months up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Dermatology and Allergy, University Hospital Schleswig-Holstein

    Kiel, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.